For a study, international recommendations proposed twice-daily moisturization as the cornerstone of atopic dermatitis therapy (AD). Moisturizers must be chosen based on their clinical efficacy in enhancing the skin barrier and alleviating the symptoms of AD. Between 2006 and 2019, researchers examined the database for clinical studies evaluating daily moisturization for the treatment of AD. The efficacy of commercially accessible moisturizers required to be evaluated using objective measurements of craniometry, transepidermal water loss, or flare incidence as outcomes, and therapies needed to be available to patients right then. Moisturization (usually twice daily) dramatically strengthened the skin barrier in adults and children with AD, according to clinical research. Flare experiments conducted over a longer period of time revealed that daily moisturization reduced the frequency of flares and increased the interval between flares. Infants at high risk of acquiring AD may benefit from early moisturization. Therapeutic moisturizers for AD were made with components that target symptoms including irritation, inflammation, and a weakened skin barrier. Any moisturizer sold in the United States that claims to cure AD must contain colloidal oatmeal, according to the FDA.
By educating patients on the benefits of generously using a therapeutic moisturizer twice a day to protect the skin barrier and assist minimize the occurrence of flares, healthcare practitioners helped to improve compliance and results. Clinically proven moisturizers must provide specific recommendations based on objective, verified skin examinations.
Reference:link.springer.com/article/10.1007/s40257-020-00529-9
